• Coverage Criteria
  - Documented diagnosis of osteoporosis in a postmenopausal woman
  - Documented T-score below -2.5 OR documentation that the patient is at high risk for bone fracture
  - Documented failure to respond, intolerance, or contraindication to:
    • Two oral bisphosphonates (alendronate, ibandronate); OR
    • One oral bisphosphonate and IV zoledronic acid (Reclast); OR
    • One oral bisphosphonate and denosumab (Prolia)
  - Documented severe osteoporosis with continued fracture after one year of continuous bisphosphonate use
  - Patients with severe osteoporosis (T-score ≤ -3 or several vertebral fractures) can bypass trial with bisphosphonates/Prolia

• Exclusion Criteria
  - Combination therapy involving the use of romosozumab concurrently with another bone mineral density modifying drug
  - Treatment of osteopenia
  - Previous treatment with Forteo or Tymlos

• Approval Period
  - 12 months (lifetime)

• Additional Notes
  - Evenity (romosozumab) is only covered under the medical specialty benefit per outlined criteria
  - Lifetime maximum duration for approval is 12 months